Fig. 1.

Interactions between BAFF receptors (BAFF-R, TACI, BCMA) and their ligands (BAFF, APRIL) and interventions targeting these molecules. BAFF can bind to all of BAFF-R, TACI, and BCMA, whereas APRIL can bind to TACI and BCMA. Because belimumab and tabalumab are monoclonal anti-BAFF antibodies, these will block BAFF-mediated signaling through BAFF-R, TACI, and BCMA. On the other hand, atacicept is a TACI-based decoy receptor and can inhibit both BAFF and APRIL. LMY-920 is a BAFF-CAR-T and then can target cells expressing any of the BAFF receptors